Literature DB >> 26118976

Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.

J Orbe1, N Alexandru2, C Roncal3, M Belzunce3, P Bibiot3, J A Rodriguez3, J C M Meijers4, A Georgescu2, J A Paramo3.   

Abstract

BACKGROUND: Thrombin-activatable fibrinolysis inhibitor (TAFI) plays an important role in coagulation and fibrinolysis. Whereas TAFI deficiency may lead to a haemorrhagic tendency, data from TAFI knockout mice (TAFI-/-) are controversial and no differences have been reported in these animals after ischemic stroke. There are also no data regarding the role of circulating microparticles (MPs) in TAFI-/-.
OBJECTIVES: to examine the effect of tPA on the rate of intracranial haemorrhage (ICH) and on MPs generated in a model of ischemic stroke in TAFI-/- mice.
METHODS: Thrombin was injected into the middle cerebral artery (MCA) to analyse the effect of tPA (10mg/Kg) on the infarct size and haemorrhage in the absence of TAFI. Immunofluorescence for Fluoro-Jade C was performed on frozen brain slides to analyse neuronal degeneration after ischemia. MPs were isolated from mouse blood and their concentrations calculated by flow cytometry.
RESULTS: Compared with saline, tPA significantly increased the infarct size in TAFI-/- mice (p<0.05). Although plasma fibrinolytic activity (fibrin plate assay) was higher in these animals, no macroscopic or microscopic ICH was detected. A positive signal for apoptosis and degenerating neurons was observed in the infarct area, being significantly higher in tPA treated TAFI-/- mice (p<0.05). Interestingly, higher numbers of MPs were found in TAFI-/- plasma as compared to wild type, after stroke (p<0.05).
CONCLUSIONS: TAFI deficiency results in increased brain damage in a model of thrombolysis after ischemic stroke, which was not associated with bleeding but with neuronal degeneration and MP production.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Circulating cell-derived microparticles; Fibrinolysis; Inflammation; TAFI; Thrombolytic therapy

Mesh:

Substances:

Year:  2015        PMID: 26118976     DOI: 10.1016/j.thromres.2015.06.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

2.  Intravenous Administration of Allogenic Cell-Derived Microvesicles of Healthy Origins Defend Against Atherosclerotic Cardiovascular Disease Development by a Direct Action on Endothelial Progenitor Cells.

Authors:  Nicoleta Alexandru; Eugen Andrei; Florentina Safciuc; Emanuel Dragan; Ana Maria Balahura; Elisabeta Badila; Adriana Georgescu
Journal:  Cells       Date:  2020-02-12       Impact factor: 6.600

Review 3.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

4.  Construction of a Health Management Model for Early Identification of Ischaemic Stroke in Cloud Computing.

Authors:  Yuying Yang; Qing Chang; Jing Chen; Xiangkun Zhou; Qian Xue; Aixia Song
Journal:  J Healthc Eng       Date:  2022-03-22       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.